BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo
Confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
The review found no eligible studies for this question.
BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in all‐cause mortalityg compared with placebo (low certainty).
The review found no eligible studies for this question.
BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
The review found no eligible studies for this question.